PRLOG

Title

Pharmaceutical Technology | Drug Development News & Views Updated Daily

Keywords

n/a

Description

Pharmaceutical news and in-depth feature articles on the new drug discoveries, healthcare research and development, big pharma trends and company deals.

Кодировка

UTF-8

Размер страницы

150.86 КБ

Количество слов

1 213

Длина текста на странице

9 927 симв.

Длина текста без пробелов

8 562 симв.

<H1>

<H2>

• All sections
• PrEP drugs: is the NHS letting down patients at risk of HIV?
• Off-the-shelf CAR-T therapy: broadening the reach of precision medicine
• Can new therapies tackle the burden of endometriosis?
• Janssen’s esketamine nasal spray approved in the EU
• Breast cancer timeline: charting three decades of success
• Syncona invests $80m in Freeline’s systemic disease gene therapies
• Bias remorse: are cancer drug trials clear enough on outcomes?
• Latest News
• Expert commentary & analysis from GlobalData
• Most Read
• Company releases
• Company whitepapers
• Company A-Z
• Read our magazine
• Projects
• Clinical Trials
• Design
• Drug Development
• Market Data
• Technology
• Your recommended content

<H3>

• Season’s Greetings
• AstraZeneca sells Arimidex and Casodex rights for $181m
• Merck secures FDA authorisation for Ebola vaccine Ervebo
• GEDmatch acquired by forensic genetic company Verogen
• Sanofi terminates diabetes research following struggle to remain competitive
• Sartan scandal investigation continues as more than 1,000 drugs use commonly out...
• Sarepta obtains surprise approval for DMD drug as FDA reverses its decision
• EL-SIE Range: Software-Free, Next-Generation Data Logging
• Kinaxis Reimagines Supply Chain Ecosystems
• Ace Your Next Display Project with PanelPilot
• Gerresheimer Increases Plastic Container Production, Opening India Plant
• Dr Beatrice Setnik Takes Over as Altasciences’ Chief Scientific Officer
• Pharmaceutical Cold Chain Management
• Discharging Drums for Loss-in-Weight Systems
• Elemental Impurity Analysis in Pharmaceuticals and Implementation of ICH Q3D
• Sanofi Active Ingredient Solution’s Product List 2019
• Considerations and Options for Prefilled Syringes
• Biopharmaceuticals and Liposomal Formulations
• IoT Tracking and Monitoring
• Rentschler Biopharmaceutical Manufacturing Facility Expansion
• Novartis Stein Cell and Gene Therapy Facility
• Parsolex’s CGMP Manufacturing Facility Expansion, West Lafayette, Indiana
• HALIX cGMP Biopharmaceutical Facility, Leiden
• Cobra Biologics Manufacturing Facility Expansion, Matfors
• Promethera closes Series D funding round to support expansion
• Data shows non-inferiority of SC administration of Roche’s Perjeta and Herceptin
• Janssen’s Darzalex outperforms standard of care in newly diagnosed multiple myel...
• ViiV submits NDA for drug indicated for multi-drug resistant HIV
• ImCheck raises Series B funds to develop gamma delta therapies
• Almirall signs deal for Iktos’ AI technology in drug design
• USPTO reverses decision regarding interfering CRISPR patents
• Dassault to enhance clinical tech with $5.8bn Medidata acquisition
• ProAmpac updates child-resistant pouch product line
• GBT and Syros team up on new therapies for blood disorders
• Syncona invests $80m in Freeline’s systemic disease gene therapies
• Triplet Therapeutics launches to focus on Huntington’s disease drugs
• CRUK partners with Vaccitech on NSCLC immunotherapeutic vaccine
• Promethera closes Series D funding round to support expansion
• US proposes rules for drug importation from Canada
• Roche gets UK and US clearances for Spark Therapeutics acquisition
• WHO announces pilot for insulin prequalification
• Allergan’s Forest to pay $750m to resolve Namenda lawsuit
• Amgen to phase out high price version of Repatha
• Almirall signs deal for Iktos’ AI technology in drug design
• Flagship Pioneering launches Cellarity for cell behaviour drugs
• Boehringer partners with Healx for AI-based drug discovery
• Novartis partners with Amazon for digital boost to manufacturing
• Orexo acquires US rights to commercialise vorvida
• Supporting mental health in a business environment
• Download a free 10 page preview of our Mergers & Acquisitions in TMT – Thematic ...

Анализ текста

• 2.31% ( 28 ) drug
• 1.24% ( 15 ) company
• 1.24% ( 15 ) pharmaceutical
• 1.24% ( 15 ) with
• 0.99% ( 12 ) development
• 0.91% ( 11 ) comment
• 0.91% ( 11 ) news
• 0.91% ( 11 ) technology
• 0.82% ( 10 ) manufacturing
• 0.82% ( 10 ) system
• 0.74% ( 9 ) analysis
• 0.74% ( 9 ) solution
• 0.66% ( 8 ) clinical
• 0.66% ( 8 ) project
• 0.66% ( 8 ) release
• 0.66% ( 8 ) research
• 0.66% ( 8 ) services
• 0.66% ( 8 ) view
• 0.58% ( 7 ) article
• 0.58% ( 7 ) close

Данные предоставлены сервисом semrush

Сайт	Общие фразы	PR	тИЦ	Alexa Rank	Alexa Country
fiercepharmamanufacturing.com	68	6	10	820950	213360
in-pharmatechnologist.com	67	6	20	486342	203379
contractpharma.com	44	5	10	320817	124356
sanofi.com	42	6	80	95720	11858
pharmamanufacturing.com	37	5	10	483734	287594
sanofipasteur.us	29	6	0	1766907	482686
jazdlifesciences.com	28	4	0	787276	Нет данных
worldpharmanews.com	26	4	10	1798160	176192
sanofipasteur.com	25	6	10	1020734	Нет данных
wikipedia.org	11	9	0	5	6
linkedin.com	8	9	0	25	10
aapsbuyersguide.com	5	5	0	5793280	Нет данных
youtube.com	5	9	0	2	2
gelifesciences.com	5	6	0	105502	50870
dhl-discoverlogistics.com	4	3	0	836262	127779
gehealthcare.co.uk	4	n/a	0	629838	450682
fishersci.com	4	7	20	16262	3594
facebook.com	4	9	0	3	3
ge.com	3	7	0	12328	5294
grundfos.com	3	6	0	31203	2749
Еще 30 сайтов после авторизации

Данные предоставлены сервисом semrush

Domain Name: PHARMACEUTICAL-TECHNOLOGY.COM
Registry Domain ID: 29594494_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.lcn.com
Registrar URL: http://www.LCN.com
Updated Date: 2017-10-12T15:58:18Z
Creation Date: 2000-06-20T12:13:23Z
Registry Expiry Date: 2019-06-20T12:13:23Z
Registrar: LCN.COM Ltd.
Registrar IANA ID: 602
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS-1218.AWSDNS-24.ORG
Name Server: NS-1622.AWSDNS-10.CO.UK
Name Server: NS-319.AWSDNS-39.COM
Name Server: NS-672.AWSDNS-20.NET

URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-11-29T11:06:50Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

User-agent: *

Allow: /
Disallow: /wp-admin/
Sitemap: https://www.pharmaceutical-technology.com/news-sitemap.xml
Sitemap: https://www.pharmaceutical-technology.com/video-sitemap.xml
Sitemap: https://www.pharmaceutical-technology.com/sitemap_index.xml

IP адрес

Дания - 193.3.2.218

Организация

Grundfos Holding A/s

Интернет провайдер

Tele Danmark

HTTP/1.1 200 OK
Connection: keep-alive
Content-Length: 154483
Cache-Control: public, max-age=6000
Content-Type: text/html; charset=UTF-8
Link: ; rel="https://api.w.org/"
Server: nginx
Strict-Transport-Security: max-age=31536000
Strict-Transport-Security: max-age=300
X-Content-Type-Options: nosniff
X-Frame-Options: SAMEORIGIN
X-Pantheon-Styx-Hostname: styx-fe4-a-b658579fc-mtc28
X-Styx-Req-Id: d2cd3f92-2bc4-11ea-b54e-32b466257857
X-Xss-Protection: 0
Date: Tue, 31 Dec 2019 11:58:16 GMT
X-Served-By: cache-mdw17358-MDW, cache-bwi5021-BWI
X-Cache: MISS, MISS
X-Cache-Hits: 0, 0
X-Timer: S1577793494.832958,VS0,VE2286
Vary: Accept-Encoding, Cookie, Cookie
Age: 0
Accept-Ranges: bytes
Via: 1.1 varnish

Проиндексирован

• Mail.ru
• Yahoo.com
• Bing.com
• Картинки Google
• Картинки Yandex

Ссылаются

• Яндекс Блоги
• Google Блоги
• Bing.com
• Ответы Mail.ru
• Записи Twitter.com

Дополнительные ссылки

• Все сайты на этом IP
• Сохраненная копия Google
• Проверка склейки
• Проверка валидности HTML
• Проверка валидности CSS
• Ping / Traceroute / DNS
• История сайта
• История владельцев